Validation of Next Generation Cerebral and Tissue Oximeter

Inclusion Criteria: 1. Healthy, male or female subjects between the ages of 18 to ≤46 years; 2. Completion of a health screening for a medical history by a licensed physician, nurse practitioner or physician assistant; 3. Minimum weight 40kg; 4. BMI within range 18.0 - 30.0. Exclusion Criteria: 1. Prior or known allergies to lidocaine (or similar pharmacologic agents, e.g., Novocain) \[self-reported\]; 2. Prior known severe allergies to medical grade adhesive/tape (Band-Aid) \[self-reported\]; 3. Taking any medication other than birth control \[self-reported\]; 4. Is currently participating in, or has recently participated in (discontinued within 30 days prior to the hypoxia procedure for this study) in an investigational drug, device, or biologic study \[self-reported\]; 5. Has a negative Allen's Test to confirm non-patency of the collateral artery \[clinical assessment by PI or delegate\]; 6. Has made a whole blood donation or has had at least 450 ml of blood drawn within 8 weeks prior to the study procedure \[self-reported\]; 7. Is female with a positive pregnancy test \[serum or urine\], or is female and is unwilling to use effective birth control between the time of screening and study procedure or is breastfeeding; 8. Has anemia \[lab values specific for gender\]; 9. Has a history of sickle cell trait or thalassemia \[self-reported\]; 10. Has an abnormal hemoglobin electrophoresis test \[lab measurement\]; 11. Has a positive urine cotinine test or urine drug screen or oral ethanol test \[POC testing\]; 12. Has a room air saturation less than 95% by pulse oximetry \[measurement by PI or delegate\]; 13. Has a clinically significant abnormal ECG \[assessment by PI or delegate\]; 14. Has a clinically significant abnormal pulmonary function test via spirometry \[assessment by PI or delegate\]; 15. Has a COHb greater than 3%, or MetHb greater than 2% \[measured by venous blood sample co-oximetry\]